Ligon Discovery and Lycera collaborate to develop first-in-class drugs for immune disorders

Cambridge, Massachusetts, February 09, 2010 – Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders....click below for full press release

Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman

20-year Industry Veteran Brings Extensive Experience in Drug Discovery and Development

Cambridge-based Ligon Discovery Raises $1M in Seed Funding

Harvard University Spinout is Pursuing Drugs for Intractable Disease Targets

Cambridge, Massachusetts, November 19, 2009 – Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With this investment, incTANK Ventures General Partner Christian Bailey joins the board...click below for full press release.